

Sartorius AG
2013 Financial Statements

2013

Contents

01 Financial Statements and Notes

- 4 Balance Sheet
- 5 Statement of Profit and Loss
- 6 Notes to the Individual Balance Sheet Items
- 10 Notes to the Statement of Profit and Loss
- 13 Remuneration Report
- 18 Declaration of the Executive Board
- 19 Independent Auditors' Report

02 Supplementary Information

- 21 Major Affiliates and Ownership in 2013
- 24 Executive Board and Supervisory Board | Positions Held
- 28 About This Publication

Forward-looking Statements Contain Risks

This annual report contains statements concerning the future performance of Sartorius AG. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually apply. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.

This is a translation of the original German-language financial statements. Sartorius shall not assume any liability for the correctness of this translation. The origi-

nal German financial statements are the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided.

Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Throughout these financial statements, differences may be apparent as a result of rounding during addition.

Financial Statements and Notes

01

Balance Sheet

Assets	Notes		Dec. 31, 2013 € in K	Dec. 31, 2012 € in K
A. Assets				
I. Property, plant and equipment	(4)		7,161	5,659
II. Financial assets	(5)		468,253	468,288
			475,414	473,947
B. Current assets				
I. Trade and other receivables	(6)		35,493	51,202
II. Cash on hand, deposits in banks			296	471
			35,789	51,673
C. Prepaid expenses	(7)		1,109	1,532
			512,312	527,152

Equity and Liabilities	Notes	€ in K	Dec. 31, 2013 € in K	Dec. 31, 2012 € in K
A. Equity				
I. Subscribed capital	(8)	18,720		18,720
Nominal value of treasury shares		-1,673		-1,673
Issued capital			17,047	17,047
II. Capital reserves			101,397	101,397
III. Earnings reserves	(9)		10,867	10,867
IV. Retained profit incl. net profit	(9)		146,245	158,992
			275,556	288,303
B. Provisions	(10)		23,582	22,490
C. Liabilities	(11)		210,252	216,359
D. Deferred tax liabilities	(26)		2,922	0
			512,312	527,152

Statement of Profit and Loss

	Notes	2013 € in K	€ in K	2012 € in K
1. Sales revenue	(15)	2,921		6,667
2. Other operating income	(16) (24)	332		476
			3,253	7,143
3. Employee benefits expense	(17)	2,991		3,948
4. Depreciation and amortization expense	(18)	240		235
5. Other operating expenses	(19) (24)	4,261		4,592
6. Income from investments	(20)	11,221		9,770
7. Profit reported due to a profit and loss transfer agreement	(21)	8,306		305
8. Loss reported due to a profit and loss transfer agreement	(22)	1,474		0
			10,561	1,301
9. Earnings before interest and taxes			13,814	8,444
10. Interest and similar income	(23)	471		1
11. Interest and similar expenses	(23)	6,454		5,952
			-5,983	-5,951
12. Profit before tax			7,831	2,493
13. Income tax expense Income from income tax	(25) (26)	4,352		-250
14. Other taxes		31		1
			4,383	-249
15. Net profit			3,448	2,742
16. Profit brought forward			142,797	156,250
17. Retained profit			146,245	158,992

Notes to the Individual Balance Sheet Items

1. Accounting and Valuation Methods

The financial statements for Sartorius AG were prepared according to the rules of the German Commercial Code (HGB) and the German Stock Corporation Law (AktG).

The accounting and valuation methods of the previous reporting year were retained.

2. Structure of the Balance Sheet and the Statement of Profit and Loss

To enhance the clarity of the presentation, items on the individual balance sheet and the statement of profit and loss have been combined and reported separately in the Notes.

4. Property, Plant and Equipment

	Land and leasehold rights and improvements, including buildings on third-party land € in K	Technical equipment and machinery € in K	Other equipment, factory and office equipment € in K	Payments on account relating to plant and equipment and construction in progress € in K	Total € in K
Property, plant and equipment developed as follows:					
Gross book values as of Jan. 1, 2013	8,000	0	200	70	8,270
Investments	808	0	23	911	1,742
Disposals	0	0	3	0	3
Transfers	0	0	0	0	0
Gross book values as of Dec. 31, 2013	8,808	0	220	981	10,009
Depreciation as of Jan. 1, 2013	2,426	0	186	0	2,612
Depreciation in 2013	233	0	6	0	239
Disposals	0	0	3	0	3
Transfers	0	0	0	0	0
Depreciation as of Dec. 31, 2013	2,659	0	189	0	2,848
Net book values as of Dec. 31, 2013	6,149	0	31	981	7,161
Net book values as of Dec. 31, 2012	5,574	0	14	70	5,658

Property, plant and equipment are reported at acquisition cost or production cost and, if subject to depreciation, are depreciated as scheduled.

German tax simplification methods are applied, provided that these are compatible with the German commercial principles of proper accounting. Where diminution in value is anticipated over the long term, unscheduled impairment losses are recorded.

3. Currency Translation

Liabilities in foreign currencies whose remaining term does not exceed one year are measured at the average spot rate valid on the reporting date. All other liabilities in foreign currencies are measured at their conversion rate upon the invoice date or the higher average spot rate on the reporting date.

Receivables in foreign currencies whose remaining term does not exceed one year are measured at the average spot rate valid on the reporting date. All other receivables in foreign currencies are measured at their conversion rate upon the invoice date or the higher average spot rate on the reporting date.

Amortization | depreciation of fixed assets is based on the following periods of useful life:

Buildings	25 to 33 years
Office equipment	3 to 13 years

5. Financial Assets

	Shares in affiliated companies € in K	Participating interests € in K	Total € in K
Financial assets changed as follows:			
Gross book values as of Jan. 1, 2013	469,045	397	469,442
Investments	5,356	0	5,356
Disposals	5,391	0	5,391
Transfers	0	0	0
Gross book values as of Dec. 31, 2013	469,010	397	469,407
Impairment losses as of Jan. 1, 2013	757	397	1,154
Impairment losses in 2013	0	0	0
Disposals	0	0	0
Additions	0	0	0
Impairment losses as of Dec. 31, 2013	757	397	1,154
Net book values as of Dec. 31, 2013	468,253	0	468,253
Net book values as of Dec. 31, 2012	468,288	0	468,288

Financial assets are accounted for at acquisition cost or at par value, unless they have to be reported at a lower recoverable amount on the balance sheet date.

Please refer to "Major Affiliates and Ownership."

6. Trade and Other Receivables

	Dec. 31, 2013 € in K	Dec. 31, 2012 € in K
Receivables from affiliated companies	33,238	49,532
Other assets	2,255	1,670
	35,493	51,202
Of which due in more than one year:		
Other assets	1,397	1,144

Trade and other receivables are reported so that all discernible risks are covered. Receivables arising from reinsurance policies that are not exempt from attachment by all creditors are recognized in the actuarial reserves according to the company's business plan.

7. Prepaid Expenses

	Dec. 31, 2013 € in K	Dec. 31, 2012 € in K
Loan discounts	1,109	1,532
Other prepaid expenses	0	0
	1,109	1,532

Loan discounts are released over the term of the respective finance loans.

8. Issued Capital

Sartorius AG's capital stock is divided into 9,360,000 bearer-type ordinary shares and 9,360,000 non-voting preference shares, each having a calculated par value of €1.00.

Between October 27, 2000, and the reporting date, 831,944 ordinary shares were repurchased at an average price of €11.27 and 840,983 preference shares were repurchased at an average price of €7.98. This corresponds to €1,673 K (8.9%) of the capital stock. In fiscal 2013, no treasury shares were purchased.

The calculated par value of the treasury shares of €1,672,927.00 was deducted from the capital stock according to Section 272, Subsection 1a, of the German Commercial Code (HGB).

Subject to approval by the Supervisory Board, the Executive Board is authorized to sell treasury shares held by the corporation, including sales through channels other than the stock exchange or by tendering an offer to all shareholders in proportion to their participation in the company, provided that these shares are offered within the scope of acquiring companies or shareholdings in companies in return. Under these circumstances, the pre-emptive rights of the shareholders are excluded.

9. Earnings Reserves and Retained Profit

The earnings reserves according to Section 266, Subsection 3 A. III, No. 4, of the German Commercial Code (HGB) remained unchanged at €10,868 K.

In fiscal 2013, the earnings reserves developed as follows:

	€ in K
At Jan. 1, 2013	158,992
– Dividends paid in 2013	–16,195
= Profit carried forward	142,797
+ Retained profit incl. net profit for 2013	3,448
At Dec. 31, 2013	146,245

10. Provisions

	Dec. 31, 2013 € in K	Dec. 31, 2012 € in K
Provisions for retirement benefits and similar obligations	16,211	16,085
Tax provisions	1,638	71
Other provisions	5,733	6,334
	23,582	22,490

Provisions for retirement benefits are set up according to actuarial principles in line with the valuation assumptions and methods pursuant to Section 249, Subsection 1, of the German Commercial Code (HGB) in conjunction with Section 253, Subsections 1 and 2, of HGB.

	Beginning of the reporting year	End of the reporting year
Accounting standards applied	HGB in the vers. of BilMoG*	
Applied assessment standards	Projected Unit Credit Method (PUCM)	
Assumptions on mortality and invalidity	Ref. interest rate table "Richttafel 2005G" from Klaus Heubeck	
Annual discount rate acc. to RückAbzinsV** (Simplification rule: interest rate for remaining period of 15 years)	5.06% (Status: Oct. 31, 2012)	4.90% (Status: Oct. 31, 2013)
Expected annual increase in old-age pensions	2.00%	2.00%
Expected annual increase in income		
– Indiv. agreed pension plans	3.00%	3.00%
– Gen. in-house retirem. plan	–	–
Annual increase in fixed amounts considered	–	–
Fluctuation	–	–
Calculated retirement age	Preretirement age	

Insolvency-protected investments in reinsurance policies to hedge obligations for early retirement benefits that were reported at a present value of €953 K (2012: €897 K) and correspond to the acquisition costs were offset against the present value of the respective retirement benefits of €1,365 K (2012: €1,269 K).

Provisions for employee retirement benefits and similar obligations developed as follows during fiscal 2013:

	€ in K
Gross provisions as of January 1, 2013	16,981,042
Interest expense	823,272
Effect of the change in the actuarial interest rate	277,967
Other change	–926,504
Gross provisions as of December 31, 2013	17,164,777
Reinsurance reserves for hedging obligations acc. to Sec. 246, Sub. 2, of HGB, as of Dec. 31, 2013 (present value of pledged reinsurance policies)	953,484
Net provisions as of December 31, 2013	16,211,293

Besides allowing for Sartorius AG's general in-house retirement plan, these provisions are set aside to meet individually agreed pension plans for active and former Executive Board members and senior corporate officers. Since the termination of the General Pension Plan "Versorgungswerk" in 1983, the portion of the general provisions is only for employees who began their employment with the company before January 1, 1983. A total of €8.4 million of the provisions set up on December 31, 2013, is allocated to Sartorius AG's general in-house retirement plan, and €8.8 million to cover individually agreed pension plans. The present values of the obligations for active Executive Board members are €938 K (2012: €820 K) to cover the pension commitment for Dr. Joachim Kreuzburg and €158 K (2012: €111 K) to cover the pension commitment for Mr. Jörg Pfirrmann, respectively. Effects from the change in accounting interest are recognized in the financial result.

The other provisions are recognized at the settlement amount for long-term provisions as are dictated by prudent business judgment. In assessing this settlement amount, all discernible risks from incomplete contracts and uncertain liabilities are considered. The other provisions with a term of less than one year are not discounted.

The other provisions include the following amounts:

	Dec. 31, 2013 € in K	Dec. 31, 2012 € in K
Employee benefits expense	3,736	3,308
Invoices outstanding	100	650
Anticipated losses related to incomplete contracts	1,390	1,861
Other	507	515
	5,733	6,334

* BilMoG = German Accounting Law Modernization Act

** RückAbzinsV = German Regulation on the Discounting of Provisions

11. Liabilities

This item consists of the following:	Disclosed on balance sheet Dec. 31, 2013 € in K	Remaining term of more than five years € in K	Remaining term of up to one year € in K	Disclosed on balance sheet Dec. 31, 2012 € in K	Remaining term of more than five years € in K	Remaining term of up to one year € in K
Liabilities to banks	136,000	50,500	13,500	149,500	50,500	13,500
Trade payables	431	0	431	156	0	156
Payables to affiliated companies	72,465	0	72,465	65,238	0	65,238
Other liabilities	1,356	0	1,356	1,465	0	1,465
	210,252	50,500	87,752	216,359	50,500	80,359

The other liabilities consist of the following:	Dec. 31, 2013 € in K	Dec. 31, 2012 € in K
Taxes	53	50
Liabilities relating to social security	0	0

Liabilities are reported as settlement amounts (amounts repayable).

12. Contingent Liabilities

	Dec. 31, 2013 € in K	Dec. 31, 2012 € in K
Guarantees and similar contingent liabilities	15,670	15,085

Guarantee and suretyship contracts for the amount of €15,670 K (2012: €15,085 K) were concluded to cover contingent liabilities arising from local credit lines granted by banks to various affiliates of Sartorius AG. These are not to be recognized because there are no signs that these subsidiaries will fail to meet their financial obligations to banks on time.

13. Disclosures on Transactions Not Included in the Balance Sheet

In addition to provisions, liabilities and contingent liabilities, other financial obligations consist of the following:

	Dec. 31, 2013 € in K	Dec. 31, 2012 € in K
Rental and leasing contracts		
– due in fiscal 2014 (previous year: due in fiscal 2013)	40	50
– due in any one fiscal year from 2015 to 2018 (previous year: due in any one fiscal year from 2014 to 2017)	31	38
	71	88

14. Derivative Financial Instruments

To hedge the company's term loan of €40 million of its syndicated credit facility agreement – which was refinanced in April 2011 – against interest rate risk, rate swaps (interest rate hedges) have been concluded with a nominal volume of €15 million and for a term until September 2015. A further interest rate swap was concluded for a nominal volume of €15 million and for a term running from March 2014 to March 2016. Moreover, the company entered into forward interest swaps with a nominal volume of €40 million and for a term running from 2016 to 2019. For existing interest hedges, a reserve of €1,390 K had to be set up for anticipated losses due to incomplete contracts (2012: €1,861 K).

Notes to the Statement of Profit and Loss

15. Sales Revenue

	2013 € in K	2012 € in K
Sales revenue, which is broken down by geographical market, was as follows:		
Germany	2,227	6,667
All other countries	694	0
Total	2,921	6,667

16. Other Operating Income

	2013 € in K	2012 € in K
Income from the release of provisions	23	150
Other income	309	326
	332	476

As in the previous year, no material income was generated by currency translation in the reporting year.

17. Employee Benefits Expense

	2013 € in K	2012 € in K
Wages and salaries	2,857	3,360
Social security	11	0
Retirement benefits expense	123	588
	2,991	3,948

In the reporting year, Sartorius AG as a holding company did not employ any staff. The employee benefits expense disclosed refers to benefits for the Executive Board of Sartorius AG.

18. Depreciation Expense

	2013 € in K	2012 € in K
Depreciation of property, plant and equipment		
Scheduled	240	235

19. Other Operating Expenses

	2013 € in K	2012 € in K
Costs for outside services	1,823	972
Remuneration for the Supervisory Board	779	753
Legal and consulting expenses	555	1,745
Travel, entertainment and representation costs	196	180
Fees and contributions	174	120
Insurance expenses	163	192
Ancillary staff costs	161	187
Car and leasing expenses	95	109
Maintenance costs	94	99
Advertising expenses	53	68
Other finance charges	30	16
Office, mail and other administrative expenses	21	32
Other expenses	117	120
	4,261	4,593

As in the previous year, no material income was generated by currency translation in the reporting year.

20. Income from Investments

	2013 € in K	2012 € in K
Income from investments	11,221	9,770

As in the previous year, the entire amount of Sartorius AG's income from investments consists of dividend payments from subsidiaries.

21. Profit Reported Due to a Profit and Loss Transfer Agreement

In fiscal 2013, Sartorius AG concluded a profit and loss transfer agreement with Sartorius Lab Holding GmbH. The amount of €8,306 K reported for this contract in the year under review is reflected in the company's earnings. The amount of €305 K disclosed for the previous year refers to income earned by Sartorius Corporate Administration GmbH in 2012.

22. Loss Reported Due to a Profit and Loss Transfer Agreement

In fiscal 2011, Sartorius AG concluded a profit and loss transfer agreement with Sartorius Corporate Administration GmbH. The amount of €1,474 K reported for this contract in the year under review is reflected in the company's earnings.

23. Interest

	2013 € in K	2012 € in K
Interest and similar income	471	1
– of which from affiliated companies	(0)	(0)
Interest and similar expenses	6,454	5,952
– of which from affiliated companies	(466)	(1,442)
	-5,983	-5,951

Interest expenses for fiscal 2013 include expenses of €1,110 K (2012: €868 K) that resulted from compounding provisions for employee retirement benefits and similar obligations.

24. Non-periodic Income and Expenses

Non-periodic income and expenses are items that do influence current results, but concern changes in transactions of the past years.

For Sartorius AG, the income to be allocated to the other business years is €23 K (2012: €150 K). This concerns income from the release of provisions. Sartorius AG did not incur any material non-periodic expenses in fiscal 2013 (2012: €0 K).

25. Income Tax Expense | Income from Income Tax

	2013 € in K	2012 € in K
Current income taxes	88	0
Deferred taxes	2,922	-250
Income taxes for the previous years	1,342	0
	4,352	-250

26. Deferred Taxes

The temporary concept is used to calculate deferred taxes. Deferred taxes are assessed for temporary differences between commercial accounting and tax accounting of assets, liabilities and prepaid expenses in Germany. This

valuation not only includes the differences arising from Sartorius AG's own balance sheet items, but also those that exist for subsidiaries ("receiving entities") or business partnerships or other non-corporate entities in which Sartorius holds an investment. Deferred taxes are assessed on the basis of the combined income tax rate for Sartorius AG, which is currently 30.0%. The combined income tax rate covers corporate income tax, industrial and commercial profits tax and the solidarity surcharge on income tax for reconstruction of eastern Germany. However, unlike in the former case, deferred taxes from temporary accounting differences for investments that have the legal form of a business partnership or a non-corporate entity are measured on the basis of a combined income tax rate, which covers only corporate income tax and the solidarity surcharge on income tax; this particular income tax rate is currently 15.83%. According to the option provided by Section 274, Subsection 1, sentence 2, of the German Commercial Code (HGB), deferred taxes are reported as amounts netted out. If an overall tax burden were to be yielded by these calculations, this would be disclosed as deferred tax liabilities. Conversely, if these calculations were to yield a tax benefit, the company would not exercise its right to elect to report this as a deferred tax asset.

In fiscal 2013, profit and loss transfer agreements were concluded between Sartorius AG and Sartorius Lab Holding GmbH, on the one hand, and between the former and Sartorius Weighing Technology GmbH, on the other hand. As a consequence, the differences in accounting between the commercial balance sheet and the tax balance sheet are now considered for the subsidiaries, or receiving entities, of Sartorius AG as the transferring entity. For this reason, the deferred tax liabilities previously recognized at the level of these receiving entities were derecognized through profit and loss in 2013 at the level of such receiving entities and recognized again through profit and loss at the level of Sartorius AG.

In the reporting year, a total balance of deferred tax liabilities of €2,922 K was yielded (2012: €0 K). Deferred tax assets result especially from the differences in the consolidated tax group for the items disclosed as "Provisions for employee retirement benefits," "Other provisions" and "Receivables." Deferred tax liabilities predominantly resulting for intangible assets, financial assets and liabilities within the entire consolidated tax group have offsetting effects.

Moreover, Sartorius AG has tax loss carry-forwards for corporate and commercial income tax as well as interest carry-forwards. Deferred tax assets were considered in their full amounts for these carry-forwards in the reporting year because from today's stance, their use is sufficiently probable. Deferred tax assets were set up for existing interest carry-forwards only in the amounts for which their use is sufficiently probable from a current viewpoint.

27. Other Disclosures

Declaration acc. to Sec. 285, No. 16, of the German Commercial Code (HGB)

The declaration prescribed by Section 161 of the German Stock Corporation Law (AktG) was submitted on December 12, 2013, and made available to the shareholders on the company's website at www.sartorius.com.

Disclosure acc. to Sec. 285, No. 17, of HGB

The consultation expenses reported under other operating expenses include the fees for services rendered by the auditing company for the following:

	2013 € in K	2012 € in K
Auditing of the annual financial statements and of the consolidated annual financial statements	66	65
Other independent reporting services	72	93
Tax consultation incl. preparation of tax returns	39	99
Other services	140	90
	317	347

Disclosure acc. to Sec. 285, No. 21, of HGB

The following table covers all business with related companies and persons for fiscal 2013:

All amounts in € in K (thousand) for fiscal 2013	Sales transactions	Purchase transactions	Financing received	Financing provided	Other transactions
Affiliated companies	0	0	21,631	33,204	1,029
Companies in which investments are held	0	0	0	0	0
Persons in key positions	0	0	0	0	0

All amounts in € in K (thousand) for fiscal 2012	Sales transactions	Purchase transactions	Financing received	Financing provided	Other transactions
Affiliated companies	0	0	18,651	48,829	4,561
Companies in which investments are held	0	0	0	0	0
Persons in key positions	0	0	0	0	0

For information on the remuneration of the Supervisory Board members and of the Executive Board members, please refer to the following section.

Remuneration Report

Remuneration of the Supervisory Board Members

€ in K	2013	2012
Total remuneration	888	860
Fixed remuneration	600	300
Performance-related remuneration	0	283
Compensation for committee work	80	60
Meeting attendance fee	104	114
Remuneration from Sartorius Weighing Technology GmbH, Goettingen	13	20
Total remuneration for the Sartorius Stedim Biotech subgroup	91	83
Remuneration from Sartorius Stedim Biotech GmbH, Goettingen	38	38
Remuneration from Sartorius Stedim Biotech S.A., Aubagne	53	45

Prof. Dr. Dres. h.c. Arnold Picot (Chairman)

Total remuneration	262	255
Fixed remuneration	120	60
Performance-related remuneration	0	56
Compensation for committee work	24	18
Meeting attendance fee	14	18
Remuneration from Sartorius Weighing Technology GmbH, Goettingen	13	20
Total remuneration for the Sartorius Stedim Biotech subgroup	91	83
Remuneration from Sartorius Stedim Biotech GmbH, Goettingen	38	38
Remuneration from Sartorius Stedim Biotech S.A., Aubagne	53	45

Gerd-Uwe Boguslawski¹⁾ (Vice Chairman)

Total remuneration	110	103
Fixed remuneration	80	40
Performance-related remuneration	0	37
Compensation for committee work	16	12
Meeting attendance fee	14	14

Dr. Dirk Basting

Total remuneration	46	45
Fixed remuneration	40	20
Performance-related remuneration	0	19
Meeting attendance fee	6	6

Annette Becker¹⁾

Total remuneration	46	45
Fixed remuneration	40	20
Performance-related remuneration	0	19
Meeting attendance fee	6	6

€ in K	2013	2012
Uwe Bretthauer¹⁾		
Total remuneration	70	69
Fixed remuneration	40	20
Performance-related remuneration	0	19
Compensation for committee work	16	12
Meeting attendance fee	14	18

Michael Dohrmann¹⁾

Total remuneration	46	45
Fixed remuneration	40	20
Performance-related remuneration	0	19
Meeting attendance fee	6	6

Dr. Lothar Kappich

Total remuneration	46	45
Fixed remuneration	40	20
Performance-related remuneration	0	19
Compensation for committee work	0	0
Meeting attendance fee	6	6

Petra Kirchhoff

Total remuneration	46	45
Fixed remuneration	40	20
Performance-related remuneration	0	19
Meeting attendance fee	6	6

Karoline Kleinschmidt¹⁾ (as of April 19, 2012)

Total remuneration	46	32
Fixed remuneration	40	14
Performance-related remuneration	0	13
Meeting attendance fee	6	5

Prof. Dr. Gerd Krieger

Total remuneration	58	56
Fixed remuneration	40	20
Performance-related remuneration	0	19
Compensation for committee work	8	6
Meeting attendance fee	10	11

¹⁾ The employee representatives declared that they donate their Supervisory Board remuneration to the foundation Hans Böckler Stiftung according to the guidelines of the German Trade Union Association "Deutscher Gewerkschaftsbund."

€ in K	2013	2012
Prof. Dr. Thomas Scheper (as of April 19, 2012)		
Total remuneration	46	32
Fixed remuneration	40	14
Performance-related remuneration	0	13
Meeting attendance fee	6	5

Prof. Dr. Klaus Rüdiger Trützschler		
Total remuneration	66	62
Fixed remuneration	40	20
Performance-related remuneration	0	19
Compensation for committee work	16	12
Meeting attendance fee	10	11

Christiane Benner¹⁾ (until April 19, 2012)		
Total remuneration	0	13
Fixed remuneration	0	6
Performance-related remuneration	0	6
Meeting attendance fee	0	1

Remuneration of the Executive Board Members

€ in K	2013	2012
Total remuneration		
Cash benefits for the fiscal year	2,567	2,679
Fixed remuneration	1,346	1,246
Annually paid variable remuneration	548	558
Variable remuneration with multi-year components paid (fair value)	673	875
Change in the fair values of the variable multi-year components of remuneration from previous years	147	611
Pension commitments	165	283

Dr. Joachim Kreuzburg		
Cash benefits for the fiscal year	1,251	1,302
Fixed remuneration	654	603
Annually paid variable remuneration	268	272
Variable remuneration with multi-year components paid (fair value)	329	427
Change in the fair values of the variable multi-year components of remuneration from previous years	74	366
Pension commitments	118	172

€ in K	2013	2012
Prof. Dr. rer. nat. Dr.-Ing. Heribert Offermanns (until April 19, 2012)		
Total remuneration	0	13
Fixed remuneration	0	6
Performance-related remuneration	0	6
Meeting attendance fee	0	1

Beyond their Supervisory Board remuneration, the employee representatives who are employees within the Sartorius Group receive compensation that is not related to their service on the Supervisory Board.

€ in K	2013	2012
Jörg Pfirrmann		
Cash benefits for the fiscal year	547	575
Fixed remuneration	288	269
Annually paid variable remuneration	116	119
Variable remuneration with multi-year components paid (fair value)	143	187
Change in the fair values of the variable multi-year components of remuneration from previous years	29	103
Pension commitments	47	111

Reinhard Vogt		
Cash benefits for the fiscal year	769	801
Fixed remuneration	404	374
Annually paid variable remuneration	164	166
Variable remuneration with multi-year components paid (fair value)	201	261
Change in the fair values of the variable multi-year components of remuneration from previous years	44	142

¹⁾ The employee representatives declared that they donate their Supervisory Board remuneration to the foundation Hans Böckler Stiftung according to the guidelines of the German Trade Union Association "Deutscher Gewerkschaftsbund."

Variable Remuneration Determined Using Multi-year Assessment

€ in K	Fair value when granted as of Jan. 1 of the particular year	Fair value when granted at year-end on Dec. 31, 2012	Fair value when granted at year-end on Dec. 31, 2013	Change in value in fiscal 2013
Dr. Joachim Kreuzburg				
Granted for fiscal 2011	138	142	136	-6
Granted for fiscal 2012	146	148	144	-5
Granted for fiscal 2013	159	0	154	-5
Total	443	290	433	-16
Jörg Pfirrmann				
Granted for fiscal 2011	63	64	62	-3
Granted for fiscal 2012	64	65	63	-2
Granted for fiscal 2013	69	0	67	-2
Total	196	130	191	-7
Reinhard Vogt				
Granted for fiscal 2011	85	88	84	-4
Granted for fiscal 2012	90	91	88	-3
Granted for fiscal 2013	97	0	94	-3
Total	271	178	265	-10

Components with a Long-term Incentive Effect

	Number of phantom stock units	Grant price ¹⁾ in €	Fair value when granted on Jan. 1 of the particular year € in K	Fair value at year-end on Dec. 31, 2012 € in K	Fair value at year-end on Dec. 31, 2013 € in K	Paid out in fiscal 2013 € in K	Change in fair value in fiscal 2013 € in K	Status
Dr. Joachim Kreuzburg								
Tranche for fiscal 2007	3,593	34.79	125	249	0	249	0	Paid out in 2013
Tranche for fiscal 2010	8,715	15.78	138	334	344	0	10	Not exercisable
Tranche for fiscal 2011	5,165	26.62	138	323	333	0	10	Not exercisable
Tranche for fiscal 2012	4,416	33.12	146	279	344	0	65	Not exercisable
Subtotal of tranches from previous years	21,889		547	1,185	1,021	249	85	
Tranche for fiscal 2013	2,289	69.36	159	0	175	0	16	Not exercisable
Total tranches	24,178		706	1,185	1,196	249	101	
Jörg Pfirrmann								
Tranche for fiscal 2010	3,334	15.78	53	128	132	0	4	Not exercisable
Tranche for fiscal 2011	2,348	26.62	63	147	152	0	5	Not exercisable
Tranche for fiscal 2012	1,937	33.12	64	122	147	0	25	Not exercisable
Subtotal of tranches from previous years	7,619		180	397	431	0	34	
Tranche for fiscal 2013	990	69.36	69	0	76	0	7	Not exercisable
Total tranches	8,609		249	397	507	0	41	
Reinhard Vogt								
Tranche for fiscal 2010	4,754	15.78	75	182	187	0	5	Not exercisable
Tranche for fiscal 2011	3,193	26.62	85	200	206	0	6	Not exercisable
Tranche for fiscal 2012	2,699	33.12	90	170	210	0	40	Not exercisable
Subtotal of tranches from previous years	10,646		250	552	603	0	51	
Tranche for fiscal 2013	1,397	69.36	97	0	107	0	10	Not exercisable
Total tranches	12,043		347	552	710	0	61	

Through the issue of shadow shares, called phantom stock, Executive Board members are treated as if they were owners of a certain number of shares in Sartorius AG, without, however, being entitled to receive dividends. The development of the value of this phantom stock is linked with the development of the Sartorius share; both increases and decreases in the

share price are taken into account. Later, the value of this phantom stock is assessed based on the share price at the time, and its equivalent is paid out, provided that the associated conditions are met. Phantom stock cannot be traded and does not entail any share subscription rights.

¹⁾ 1) Average share price over the last 20 days of trading in the preceding fiscal year

Specifically, the company's phantom stock plan credits each Executive Board member at the beginning of every year with phantom stock units valued at an agreed monetary sum. The value of this phantom stock can be paid out only as an entire annual tranche, and such phantom stock options may be exercised no earlier than four years and no later than eight years after this sum has been credited.

An Executive Board member is entitled to receive payment for phantom stock units only if the share price at the time of such payment requests has appreciated at least 7.5% per year relative to the time the phantom stock was assigned or if the share price outperformed the TecDAX as a comparative index. The phantom stock plan rules out subsequent changes to the parameters used for comparative stock valuation. The amount to be paid is capped at a maximum of 2.5 times the share price at the time the phantom stock was assigned, based in each case on the actual annual tranche concerned.

Assignment of this phantom stock and payment of its monetary equivalent depend on the mean value calculated from the average prices of both classes of Sartorius AG share in the closing auction of Xetra trading on the Frankfurt Stock Exchange over the last 20 days of trading prior to submission of a payment request. This serves to compensate for any short-term fluctuations in the share prices.

Payment for phantom stock is blocked for the four weeks preceding the scheduled publication date of quarterly and preliminary year-end results and for 20 days of trading on the stock exchange following the actual publication of quarterly and preliminary year-end results. These blackout periods are intended to prevent Executive Board members' profiting from their insider knowledge.

Remuneration and Pension Obligations for Former Managing Directors

	2013 € in K	2012 € in K
Remuneration of former managing directors and members of the Executive Board and their surviving dependents	394	386
Retirement benefits and pension obligations to former managing directors and members of the Executive Board as well as their surviving dependents	7,065	7,045

Number of Employees

No staff members were employed in the reporting year.

Proposal for Appropriation of Profits

The Executive Board will submit a proposal to the Annual Shareholders' Meeting to appropriate the retained profit of €146,244,628.19 reported by Sartorius AG for the year ended December 31, 2013, as follows:

	€
Payment of a dividend of €1.00 per ordinary share	8,528,056.00
Payment of a dividend of €1.02 per preference share	8,689,397.34
Unappropriated profit carried forward	129,027,174.85
	146,244,628.19

Disclosure acc. to Section 160, Subsection 1, No. 4, of the German Stock Corporation Law (AktG)

Subject to approval by the Supervisory Board, the Executive Board is authorized to sell treasury shares held by the corporation, including sales through channels other than the stock exchange or by tendering an offer to all shareholders in proportion to their participation in the company, provided that these shares are offered within the scope of acquiring companies or shareholdings in companies in return. Under these circumstances, the pre-emptive rights of the shareholders are excluded.

Disclosure acc. to Section 160, Subsection 1, No. 8, of the German Stock Corporation Law (AktG)

The following information was available as of December 31, 2013, according to Section 21, Subsection 1 or 1a, of the German Securities Trading Act (WpHG).

1. Mrs. C. Franken, a legal resident of Bovenden, Germany, notified us that as of April 1, 2002, she has held 3.66% of her own voting rights and 55.59% of the voting rights in the company's share capital as a member of the community of heirs regarding the estate of Horst Sartorius; i.e., her share of total voting rights is 59.25% and has thus exceeded the threshold of 50%.

2. Mrs. U. Baro, a legal resident of Munich, Germany, notified us that as of April 1, 2002, she has held 4.99% of her own voting rights and 55.59% of the voting rights in the company's share capital as a member of the community of heirs regarding the estate of Horst Sartorius; i.e., her share of total voting rights is 60.58% and has thus exceeded the threshold of 50%.

3. Mrs. K. Sartorius, a legal resident of Northeim, Germany, notified us that as of April 1, 2002, she has held 7.54% of her own voting rights and 55.59% of the voting rights in the company's share capital as a member of the community of heirs regarding the estate of Horst Sartorius; i.e., her share of total voting rights is 63.13% and has thus exceeded the threshold of 50%.

4. Prof. A. Picot, who holds a doctorate and is a legal resident of Gauting, Germany, notified us in his capacity as executor of Horst Sartorius' estate that as of April 1, 2002, he has held 55.59% of the voting rights in the company's share capital on account of the voting rights attributed pursuant to Section 22, Subsection 1, sentence no. 1, no. 6, of the German Securities Trading Act (WpHG) and has thus exceeded the threshold of 50%.

5. Bio-Rad Laboratories Inc., based in Hercules, California, notified us that as of April 6, 2011, it has held 30.01% of the voting rights in the company's share capital on account of the voting rights attributed pursuant to Section 22, Subsection 1, sentence no. 1, of the German Securities Trading Act (WpHG) and has thus exceeded the threshold of 30%.

6. Mr. Andreas Franken, a resident of Germany, notified us pursuant to Section 21, Subsection 1, of the German Securities Trading Act (WpHG) that he as a purchaser of a share of the undivided estate of Horst Sartorius in Sartorius AG exceeded the thresholds of 3%, 5%, 10%, 15%, 20%, 25%, 30% and 50% on December 28, 2010. On this date, he was entitled to 58.98% of the voting rights in Sartorius AG. This corresponds to 5,520,484 voting rights. Of this total percentage, 50.09%, corresponding to 4,688,540 voting rights, are to be attributed to Mr. Andreas Franken as he is a member of the community of heirs regarding the estate of Horst Sartorius. These vot-

ing rights continue to be subject to administration by the executor. The remaining percentage of 8.89%, corresponding to 831,944 voting rights, is to be attributed to Mr. Andreas Franken pursuant to Section 22, Subsection 1, sentence 1, no. 1, of WpHG. These voting rights are held as treasury shares directly by Sartorius AG, the company that is under the direct control of the community of heirs regarding the estate of Horst Sartorius.

7. Mr. Kai-Christian Franken, a resident of Germany, notified us pursuant to Section 21, Subsection 1, of the German Securities Trading Act (WpHG) that he as a purchaser of a share of the undivided estate of Horst Sartorius in Sartorius AG exceeded the thresholds of 3%, 5%, 10%, 15%, 20%, 25%, 30% and 50% on December 28, 2010. On this date, he was entitled to 58.98% of the voting rights in Sartorius AG. This corresponds to 5,520,484 voting rights. Of this total percentage, 50.09%, corresponding to 4,688,540 voting rights, are to be attributed to Mr. Kai-Christian Franken as he is a member of the community of heirs regarding the estate of Horst Sartorius. These voting rights continue to be subject to administration by the executor. The remaining percentage of 8.89%, corresponding to 831,944 voting rights, is to be attributed to Mr. Kai-Christian Franken pursuant to Section 22, Subsection 1, sentence 1, no. 1, of WpHG. These voting rights are held as treasury shares directly by Sartorius AG, the company that is under the direct control of the community of heirs regarding the estate of Horst Sartorius.

We did not receive any further notices.

Goettingen, February 10, 2014

Sartorius Aktiengesellschaft
The Executive Board

Declaration of the Executive Board

We declare to the best of our knowledge that the year-end financial statements for fiscal 2013 present a true and fair view of the actual net worth, financial situation and profitability of the company in accordance with the accounting standards used in preparing these statements. We also certify that the progress of the company's business, including its business performance and its situation, are represented accurately in the Group

Management Report in all material respects and present the most important opportunities and risks of the company's future development during the fiscal year.

Goettingen, Monday, February 10, 2014


Sartorius Aktiengesellschaft
The Executive Board



Dr. Joachim Kreuzburg



Jörg Pffirmann



Reinhard Vogt

Independent Auditors' Report

We audited the year-end financial statements – consisting of the balance sheet, statement of profit and loss and the notes to the financial statements – including the accounting records and the management report of Sartorius Aktiengesellschaft (AG), Goettingen, Germany, which is integrated into the Group Management Report, for the fiscal year from January 1 to December 31, 2013. Accounting and preparation of the annual financial statements and of the management report according to the German commercial accounting standards are the responsibility of the Executive Board of Sartorius AG. Our responsibility is to express an opinion on the company's annual financial statements, including its accounting records, and on its management report, based on our audit.

We conducted our annual audit in accordance with Section 317 of the German Commercial Code (HGB), taking into account the principles of proper auditing established by the German Institute of Independent Auditors, "Institut der Wirtschaftsprüfer." These principles require that we plan and perform the audit to obtain reasonable assurance that there are no misrepresentations and infractions that would have a material impact on the presentation of the net worth, financial position and earnings in the annual financial statements, in consideration of the accounting principles to be applied, or in the management report. In determining the audit focus, information on the business activities and the economic and legal background of the company as well as expectations concerning possible errors are considered. Within the scope of the audit, the effectiveness of the internal controlling system and evidence supporting the amounts and disclo-

tures of the accounting records, annual financial statements and the management report are predominantly examined on a test basis. This audit covers assessment of the accounting principles applied and the significant estimates made by the Executive Board as well as the overall presentation of the year-end financial statements and the management report. We believe that our audit provides a reasonable basis for our opinion.

Our audit did not result in any objections.


According to our assessment based on the information we obtained during the audit, the annual financial statements drawn up by Sartorius Aktiengesellschaft, Goettingen, Germany, present fairly, in all material respects, the net worth, financial position and earnings of the joint stock corporation in conformity with generally accepted accounting principles. The management report is consistent with the year-end financial statements and provides an overall true and fair view of the company's situation, and accurately presents the opportunities and risks of its future development.

Hanover, February 10, 2014

Deloitte & Touche GmbH
Wirtschaftsprüfungsgesellschaft
(Name of the independent auditing company)



Henning Scharpenberg
Auditor



Dr. Christian Meyer
Auditor

Supplementary Information

02

Major Affiliates and Ownership in 2013

	Sartorius AG's ownership in %	Equity at Dec. 31, 2013 € in K	Net profit at Dec. 31, 2013 € in K
Europe			
Sartorius Stedim Biotech S.A., Aubagne, France along with its subsidiaries:	74.4	121,752	20,875
Sartorius Stedim Belgium N.V., Vilvoorde, Belgium*)	100.0	1,836	762
Sartorius Stedim Nordic A/S, Taastrup, Denmark*)	100.0	357	1,310
Distribo GmbH, Goettingen, Germany****)	26.0	573	138
Sartorius Stedim Biotech GmbH, Goettingen, Germany*)	100.0	104,906	32,993
Sartorius Stedim Plastics GmbH, Goettingen, Germany*)	100.0	2,334	1,130
Sartorius Stedim Systems GmbH, Guxhagen, Germany*) ****)	100.0	9,870	0
Sartorius Stedim UK Ltd., Epsom, U.K.*)	100.0	2,456	1,725
Sartorius Stedim Lab Ltd., Louth, U.K.*)	100.0	2,015	1,400
TAP Biosystems Group Ltd., Royston, U.K.*)	100.0	-261	1,028
TAP ESOP Management Ltd., Royston, U.K.*)	100.0	7	0
TAP Biosystems (PHC) Ltd., Royston, U.K.*)	100.0	0	0
TAP Biosystems Group Ltd., Royston, U.K.*)	100.0	0	0
The Automation Partnership Cambridget Ltd., Royston, U.K.*)	100.0	6,783	823
Sartorius Stedim FMT S.A.S., Aubagne, France*)	100.0	45,810	2,870
Sartorius Stedim France S.A.S., Aubagne, France*)	100.0	10,605	3,364
Sartorius Stedim Financière S.A.S., Aubagne, France*)	100.0	0	0
Sartorius Stedim Aseptics S.A., Lourdes, France*)	100.0	5,786	2,061
Sartorius Stedim Ireland Ltd., Dublin, Ireland*)	100.0	536	135
Sartorius Stedim Italy S.p.A., Florence, Italy*)	100.0	6,613	1,776
Sartorius Stedim Netherlands B.V., Nieuwegein, Netherlands*)	100.0	1,856	315
Sartorius Stedim Austria GmbH, Vienna, Austria*)	100.0	1,196	842
Sartorius Stedim Poland Sp. z.o.o., Kostrzyn, Poland*) ***)	100.0	52	-64
OOO Sartorius ICR, St. Petersburg, Russia*) ***)	100.0	186	61
Sartorius Stedim Switzerland AG, Tagelswangen, Switzerland*)	100.0	8,568	3,029
Sartorius Stedim Spain S.A., Madrid, Spain*)	100.0	632	374
Sartorius Stedim Hungaria Kft., Budapest, Hungary*) ***)			
	100.0	342	28
North America			
Sartorius Stedim Filters Inc., Yauco, Puerto Rico*)	100.0	30,730	10,472
Sartorius Stedim North America Inc., Bohemia, New York, USA*)	100.0	67,485	11,125
The Automation Partnership Inc., Greenville, Delaware, USA*)	100.0	1,626	203
Asia Pacific			
Sartorius Stedim Australia Pty. Ltd., Dandenong South, Victoria, Australia*)	100.0	1,314	224
Sartorius Stedim Biotech (Beijing) Co. Ltd., Beijing, China*)	100.0	1,434	-623
Sartorius Stedim India Pvt. Ltd., Bangalore, India*)	100.0	3,314	825
Sartorius Stedim Japan K.K., Tokyo, Japan*)	100.0	2,963	624
Sartorius Korea Biotech Co. Ltd., Seoul, South Korea*)	49.0	6,130	2,532
Sartorius Stedim Malaysia Sdn. Bhd., Kuala Lumpur, Malaysia *)	100.0	939	570
Sartorius Stedim Singapore Pte. Ltd., Singapore*)	100.0	2,035	845
Other Markets			
Sartorius Stedim Bioprocess S.A.R.L., M'Hamdia, Tunisia*)	100.0	3	0
Sartorius Stedim Integrated Services S.A.R.L., M'Hamdia, Tunisia*)	100.0	2	0
Sartorius Stedim Biotech S.A.R.L., M'Hamdia, Tunisia*)	100.0	4	0

The companies identified by an *) are indirectly held by Sartorius Stedim Biotech S.A., France.

The equity investments in the companies that are identified by **) are indirectly held.

As the financial statements of the subsidiaries identified by ***) were not available at the time our consolidated financial statements were prepared, the information from the annual financial statements from 2012 was considered.

Profit and loss transfer agreements exist for companies identified by ****).

	Sartorius AG's ownership in %	Equity at Dec. 31, 2013 € in K	Net profit at Dec. 31, 2013 € in K
Europe			
Sartorius Belgium N.V., Vilvoorde, Belgium**)	100.0	-457	136
Sartorius Intec Belgium B.V.B.A., Vilvoorde, Belgium**)	100.0	300	0
Sartorius Nordic A/S, Taastrup, Denmark**)	100.0	311	183
Sartorius Mechatronics C&D GmbH & Co. KG, Aachen, Germany, including Sartorius-Verwaltungs-GmbH**)	100.0	-1,419	-928
Sartorius Mechatronics T&H Hamburg GmbH, Hamburg, Germany	100.0	31,306	1,845
Sartorius Weighing Technology GmbH, Goettingen, Germany**)	100.0	44,828	0
Denver Instrument GmbH, Goettingen, Germany**)	100.0	643	106
Sartorius Corporate Administration GmbH, Goettingen, Germany****)	100.0	639	0
SI Weende-Verwaltungs-GmbH, Goettingen, Germany	100.0	20	-3
SIV Weende GmbH & Co. KG, Goettingen, Germany	100.0	3,017	55
SI Grone 1-Verwaltungs-GmbH, Goettingen, Germany**)	100.0	23	0
SIV Grone 1 GmbH & Co. KG, Goettingen, Germany**)	100.0	5,107	-221
SWT Treuhand GmbH, Goettingen, Germany**)	100.0	25	0
Sartorius Lab Holding GmbH, Goettingen, Germany****)	100.0	149,581	0
Sartorius Lab Instruments GmbH & Co. KG, Goettingen, Germany**)	100.0	28,322	1,334
Sartorius Industrial Scales GmbH & Co. KG, Bovenden, Germany**)	100.0	21,275	2,730
Sartorius Industrial Weighing Verwaltungs GmbH, Bovenden, Germany**)	100.0	25	0
Sartorius UK Ltd., Epsom, U.K.**)	100.0	-708	-1,395
Sartorius Intec UK Ltd., Epsom, U.K.**)	100.0	0	0
Biohit Ltd., Torquay, U.K.**)	100.0	0	-239
Sartorius Biohit Liquid Handling Oy, Helsinki, Finland**)	100.0	6,168	508
Sartorius France S.A.S., Aubagne, France**)	100.0	849	97
VL Finance S.A.S., Aubagne, France	100.0	56,973	2,110
Sartorius Intec France S.A.S., Les Ulis, France**)	100.0	300	0
Biohit France S.A.S., Dourdan, France**)	100.0	2,015	198
Sartorius Ireland Ltd., Dublin, Ireland**)	100.0	32	-65
Sartorius Italy S.r.l., Florence, Italy**)	100.0	719	-68
Sartorius Intec Italy S.r.l., Muggiò, Italy**)	100.0	10	0
Sartorius Netherlands B.V., Rotterdam, Netherlands**)	100.0	584	260
Sartorius Intec Netherlands B.V., Rotterdam, Netherlands**)	100.0	10	0
Sartorius Austria GmbH, Vienna, Austria**)	100.0	3,004	329
Sartorius Intec Austria GmbH, Vienna, Austria**)	100.0	10	0
Sartorius Poland Sp. z o.o., Kostrzyn, Poland**)	100.0	350	-20
Sartorius Intec Poland Sp. z o.o., Kostrzyn, Poland**)	100.0	3	0
ZAO Sartogom, St. Petersburg, Russia****)	51.0	1,010	316
Biohit OOO, St. Petersburg, Russia**)	100.0	897	354
Sartorius Mechatronics Switzerland AG, Tagelswangen, Switzerland**)	100.0	-387	-106
Sartorius Spain S.A., Madrid, Spain**)	100.0	-1,346	-203
Sartorius Intec Spain S.A., Madrid, Spain**)	100.0	3	0
Sartorius Hungaria Kft., Budapest, Hungary**)	100.0	1,081	172
North America			
Sartorius North America Inc., Bohemia, New York, USA**)	100.0	23,447	0
Sartorius Corporation, Bohemia, New York, USA**)	100.0	55	-3,476
Sartorius Intec USA Inc., Wilmington, Delaware, USA **)	100.0	0	0
Sartorius Canada Inc., Mississauga, Canada**)	100.0	82	18

	Sartorius AG's ownership in %	Equity at Dec. 31, 2013 € in K	Net profit at Dec. 31, 2013 € in K
Asia Pacific			
Sartorius Australia Pty. Ltd., Dandenong South, Victoria, Australia**)	100.0	542	42
Denver Instrument (Beijing) Co. Ltd., Beijing, China**)	100.0	2,849	-29
Sartorius Scientific Instruments (Beijing) Co. Ltd., Beijing, China**)	100.0	21,170	1,392
Biohit Biotech (Suzhou) Co. Ltd., Shanghai, China**)	100.0	872	4
Sartorius Hong Kong Ltd., Kowloon, Hong Kong**)	100.0	2,619	32
Sartorius Mechatronics India Pvt. Ltd., Bangalore, India**)	100.0	4,377	175
Sartorius Weighing India Pvt. Ltd., Bangalore, India**)	100.0	1,847	-730
Biohit Biotech Systems (India) Pvt. Ltd., Chennai, India**)	100.0	-78	-103
Sartorius Japan K.K., Tokyo, Japan**)	100.0	6,534	860
Sartorius Intec K.K., Tokyo, Japan**)	100.0	553	0
Sartorius Malaysia Sdn. Bhd., Kuala Lumpur, Malaysia**)	100.0	797	585
Sartorius Mechatronics Philippines Inc., Makati City, Philippines**)	100.0	279	73
Sartorius Singapore Pte. Ltd., Singapore**)	100.0	953	215
Sartorius Korea Ltd., Seoul, South Korea**)	100.0	4,431	461
Sartorius (Thailand) Co. Ltd., Bangkok, Thailand**)	49.0	665	73
Other Markets			
Sartorius Argentina S.A., Buenos Aires, Argentina**)	98.5	853	152
Sartorius do Brasil Ltda., São Paulo, Brazil**)	100.0	-1,475	-469
Sartorius de México S.A. de C.V., Naucalpan, Mexico**)	95.0	1,353	371

The companies identified by an *) are indirectly held by Sartorius Stedim Biotech S.A., France.

The equity investments in the companies that are identified by **) are indirectly held.

As the financial statements of the subsidiaries identified by ***) were not available at the time our consolidated financial statements were prepared, the information from the annual financial statements from 2012 was considered.

Profit and loss transfer agreements exist for companies identified by ****).

Executive Board and Supervisory Board

During Fiscal 2013¹⁾

Executive Board

Dr. rer. pol. Joachim Kreuzburg

Dipl.-Ingenieur (Graduate Engineer) CEO and Chairman
Strategy, Operations, Legal Issues, Compliance
and Corporate Communications

Born April 22, 1965

Resident of Hanover, Germany

Member since November 11, 2002

Sprecher (Spokesman) from May 1, 2003,
to November 10, 2005

Chairman since November 11, 2005

Appointed until November 10, 2015

Jörg Pfirrmann

Dipl.-Ökonom (Graduate Economist)

Executive for Labor Relations

Finance, Human Resources,

IT and General Administration

Born November 30, 1972

Resident of Noerten-Hardenberg, Germany

Member since July 24, 2009

Appointed until July 23, 2017

Reinhard Vogt

Industriekaufmann (Industrial Business Manager)

Marketing, Sales and Services

Born August 4, 1955

Resident of Dransfeld, Germany

Member since July 24, 2009

Appointed until July 23, 2019

Supervisory Board

Prof. Dr. Dres. h.c. Arnold Picot

Dipl.-Kaufmann (Graduate in Business Administration)
and university professor

Chairman

Research Center for Information,

Organization and Management

Faculty of Economics of the

Ludwig Maximilian University in Munich, Germany

Resident of Gauting, Germany

Gerd-Uwe Boguslawski

Dipl.-Sozialwirt (Graduate Social Manager)

Vice Chairman

German Metalworkers' Union (IG Metall)

in the southern Lower Saxony/Harz region in

Northeim, Germany

Resident of Hoeckelheim, Germany

Dr. Dirk Basting

Dipl.-Chemiker (Graduate Chemical Engineer)

Resident of Fort Lauderdale, Florida,

USA

Annette Becker

Personalfachkauffrau (HR Specialist)

Chairwoman of the Employees' Council of

Sartorius Corporate Administration GmbH in

Goettingen, Germany Resident of Goettingen, Germany

Uwe Bretthauer

Dipl.-Ingenieur (Graduate Engineer)

Chairman of the Employees' Council of

Sartorius Lab Instruments GmbH & Co. KG and

Sartorius Industrial Scales GmbH & Co. KG

Group Employees' Council Chairman of

Sartorius AG in Goettingen, Germany

Resident of Goettingen, Germany

Michael Dohrmann

Feinmechaniker (Precision Engineer)

Chairman of the Employees' Council of

Sartorius Stedim Biotech GmbH

in Goettingen, Germany

Resident of Reinhausen, Germany

Dr. Lothar Kappich

Dipl.-Ökonom (Graduate Economist)

Managing Director of

ECE Projektmanagement GmbH & Co. KG

in Hamburg, Germany

Resident of Hamburg, Germany

¹⁾ Information required pursuant to Sec. 285, No. 10,
of the German Commercial Code (HGB)

Petra Kirchhoff

Dipl.-Volkswirtin (Graduate Political Economist)
 Vice President of Group Corporate Communications
 and Investor Relations
 Sartorius Corporate Administration GmbH
 in Goettingen, Germany
 Resident of Goettingen, Germany

Karoline Kleinschmidt

Dipl.-Sozialwirtin (Graduate Social Economist)
 Secretary of the German Metalworkers' Union
 (IG Metall) of the district management of
 Lower Saxony and Sachsen-Anhalt in Hanover, Germany
 Resident of Hanover, Germany

Prof. Dr. Gerd Krieger

Lawyer
 Honorary Professor at the
 Heinrich-Heine University in Duesseldorf, Germany
 Resident of Duesseldorf, Germany

Prof. Dr. Thomas Scheper

Dipl.-Chemiker (Graduate Chemical Engineer)
 University professor and head of the Institute of
 Technical Chemistry, Leibniz University
 in Hanover, Germany
 Resident of Hanover, Germany

Prof. Dr. Klaus Rüdiger Trützschler

Dipl.-Wirtschaftsmathematiker (Graduate Business
 Mathematician) and
 Dipl.-Mathematiker (Graduate Mathematician)
 Honorary Professor at the
 Westphalian Wilhelm University in Muenster, Germany
 Resident of Essen, Germany

Committees of the Supervisory Board**Executive Task Committee**

Prof. Dr. Dres. h.c. Arnold Picot (Chairman)
 Gerd-Uwe Boguslawski
 Uwe Bretthauer
 Prof. Dr. Gerd Krieger

Audit Committee

Prof. Dr. Klaus Rüdiger Trützschler (Chairman)
 Gerd-Uwe Boguslawski
 Uwe Bretthauer
 Prof. Dr. Dres. h.c. Arnold Picot

Conciliation Committee

Prof. Dr. Dres. h.c. Arnold Picot (Chairman)
 Gerd-Uwe Boguslawski
 Uwe Bretthauer
 Prof. Dr. Gerd Krieger

Nomination Committee

Prof. Dr. Gerd Krieger
 Prof. Dr. Dres. h.c. Arnold Picot
 Dr. Lothar Kappich

¹⁾ Information required pursuant to Sec. 285, No. 10,
 of the German Commercial Code (HGB)

Positions Held by the Members of the Executive Board¹⁾
as of December 31, 2013

Dr. rer. pol. Joachim Kreuzburg

Président-Directeur Général (CEO) of:

- Sartorius Stedim Biotech S.A., France²⁾

On the Supervisory Board of:

- Sartorius Stedim Biotech GmbH, Germany,
Vice Chairman²⁾

On the Board of Directors of:

- Sartorius North America, Inc., USA²⁾
 - Sartorius Stedim North America, Inc., USA²⁾
 - Sartorius Stedim Filters, Inc., Puerto Rico²⁾
 - Sartorius Japan K.K., Japan²⁾
 - Sartorius Stedim Japan K.K., Japan²⁾
 - Denver Instrument (Beijing) Co. Ltd., China²⁾
 - Sartorius Scientific Instruments (Beijing) Co. Ltd., China²⁾
 - Sartorius Hong Kong Ltd., China²⁾
 - Sartorius Stedim Lab Ltd., U.K.²⁾
 - Sartorius Biohit Liquid Handling Oy, Finland²⁾
 - Sartorius Stedim Biotech SARL, Tunisia²⁾
 - Sartorius Stedim Integrated Services SARL, Tunisia²⁾
 - Sartorius Stedim Bioprocess SARL, Tunisia²⁾
- On the Comité Exécutif (Executive Committee) of:
- Sartorius Stedim FMT S.A.S., France²⁾
- On the Regionalbeirat (Regional Advisory Board) of:
- Commerzbank AG, Hamburg, Germany³⁾
- On the Beirat (Advisory Board) of:
- Hameln Group GmbH, Germany³⁾
 - Otto Bock Holding GmbH & Co. KG, Germany³⁾
- On the Wirtschaftsbeirat (Economic Advisory Board) of:
- Norddeutsche Landesbank, Germany³⁾

Jörg Pfirrmann

On the Verwaltungsrat (Administrative Board) of:

- Sartorius Mechatronics Switzerland AG, Switzerland²⁾

On the Board of Directors of:

- Sartorius North America, Inc., USA²⁾
- Sartorius Corporation, USA²⁾
- Sartorius TCC Company, USA²⁾
- Sartorius Canada Inc., Canada²⁾
- Sartorius Stedim UK Ltd., U.K.²⁾
- Sartorius Stedim Biotech (Beijing) Co. Ltd.²⁾, China

On the Comité Exécutif (Executive Committee) of:

- Sartorius France S.A.S., France²⁾
- Sartorius Stedim France S.A.S., France²⁾

On the Consiglio di Amministrazione
(Board of Management) of:

- Sartorius Stedim Italy S.p.A., Italy²⁾

On the Consejo de Administración (Board of Directors) of:

- Sartorius Spain S.A., Spain²⁾
- Sartorius Stedim Spain S.A., Spain²⁾

On the Supervisory Board of:

- Sartorius Stedim Nordic A/S, Denmark²⁾
- Sartorius Nordic A/S, Denmark²⁾

On the Unternehmerbeirat (Employers' Advisory Board) of:

- Gothaer Versicherungsbank WVaG³⁾

Reinhard Vogt

On the Conseil d'Administration (Board of Directors) of:

- Sartorius Stedim Biotech S.A., France²⁾

On the Board of Directors of:

- Sartorius North America, Inc., USA²⁾
 - Sartorius Stedim North America, Inc., USA²⁾
 - Denver Instrument (Beijing) Co. Ltd., China²⁾
 - Sartorius Scientific Instruments (Beijing) Co. Ltd., China²⁾
 - Sartorius Stedim Malaysia Sdn. Bhd., Malaysia²⁾
 - Sartorius Japan K.K.²⁾, Japan
 - Sartorius Stedim Japan K.K.²⁾, Japan
 - Sartorius Hong Kong Ltd., China²⁾
 - Sartorius Korea Ltd., South Korea²⁾
 - Sartorius Australia Pty. Ltd., Australia²⁾
 - Sartorius Stedim Australia Pty. Ltd., Australia²⁾
- On the Verwaltungsrat (Administrative Board) of:
- Sartorius Stedim Switzerland AG, Switzerland Chairman²⁾

¹⁾ Information required pursuant to Section 285, No. 10, of the German Commercial Code (HGB)

²⁾ Positions held within the Group

³⁾ External positions held by members of the Executive Board as of December 31, 2013

Positions Held by the Members of the Supervisory Board¹⁾

as of December 31, 2013

Prof. Dr. Dres. h.c. Arnold Picot

On the Conseil d'Administration (Board of Directors) of:

- Sartorius Stedim Biotech S.A., France²⁾

On the Supervisory Board of:

- Sartorius Stedim Biotech GmbH, Germany, Chairman²⁾
- Takkt AG, Germany³⁾
- Wissenschaftliches Institut für Infrastruktur und Kommunikationsdienste GmbH
(Scientific Institute for Communication Services)
and WIK-Consult GmbH, Germany³⁾

Gerd-Uwe Boguslawski

On the Supervisory Board of:

- Demag Cranes & Components GmbH, Germany³⁾
- Demag Cranes AG, Germany³⁾

Dr. Dirk Basting

None

Annette Becker

None

Uwe Bretthauer

None

Michael Dohrmann

None

Dr. Lothar Kappich

None

Petra Kirchhoff

On the Supervisory Board of:

- AWO Göttingen gGmbH

Karoline Kleinschmidt

None

Prof. Dr. Gerd Krieger

On the Supervisory Board of:

- ARAG Lebensversicherungs-AG
(life insurance company), Germany³⁾
- ARAG Krankenversicherungs-AG
(health insurance company), Germany³⁾

Prof. Dr. Thomas Scheper

None

Prof. Dr. Klaus Rüdiger Trützschler

On the Supervisory Board of:

- Deutsche Bank AG, Germany³⁾
- Takkt AG, Germany, Vice Chairman³⁾
- Wuppermann AG, Germany, Chairman³⁾
- Zwiessel Kristallglas AG, Germany, Chairman³⁾

On the Verwaltungsrat (Administrative Board) of:

- Wilh. Werhahn KG, Germany³⁾

¹⁾ Information required pursuant to Section 285, No. 10, of the German Commercial Code (HGB)

²⁾ Positions held within the Group

³⁾ External positions held by members of the Executive Board as of December 31, 2013

About This Publication

Published by

Sartorius AG
Group Corporate Communications
37070 Goettingen, Germany

Editorial Deadline

February 25, 2014

Published on

Friday, February 28, 2014

Original German version
published on February 28, 2014

Sartorius AG
Weender Landstrasse 94-108
37075 Goettingen, Germany

Phone: +49.551.308.0
Fax: +49.551.308.3289

info@sartorius.com
www.sartorius.com

turning science **into solutions**